siplizumab


siplizumab

A humanised anti-CD2 monoclonal antibody for treating transplant rejection, GVHD, autoimmune disorders (e.g., psoriasis, rheumatoid arthritis), inflammatory bowel disease and CD2-positive lymphoproliferative disorders.